GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Renal Associates Holdings Inc (NYSE:ARA) » Definitions » Intrinsic Value: Projected FCF

American Renal Associates Holdings (American Renal Associates Holdings) Intrinsic Value: Projected FCF : $0.00 (As of May. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is American Renal Associates Holdings Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-12), American Renal Associates Holdings's Intrinsic Value: Projected FCF is $0.00. The stock price of American Renal Associates Holdings is $11.52. Therefore, American Renal Associates Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for American Renal Associates Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:

ARA's Price-to-Projected-FCF is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.59
* Ranked among companies with meaningful Price-to-Projected-FCF only.

American Renal Associates Holdings Intrinsic Value: Projected FCF Historical Data

The historical data trend for American Renal Associates Holdings's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Renal Associates Holdings Intrinsic Value: Projected FCF Chart

American Renal Associates Holdings Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - 14.99

American Renal Associates Holdings Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 14.99 14.35 19.60 20.82

Competitive Comparison of American Renal Associates Holdings's Intrinsic Value: Projected FCF

For the Diagnostics & Research subindustry, American Renal Associates Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Renal Associates Holdings's Price-to-Projected-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Renal Associates Holdings's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where American Renal Associates Holdings's Price-to-Projected-FCF falls into.



American Renal Associates Holdings Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get American Renal Associates Holdings's Free Cash Flow(6 year avg) = $83.57.

American Renal Associates Holdings's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep20)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*83.5744+-78.975/0.8)/33.472
=20.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Renal Associates Holdings  (NYSE:ARA) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

American Renal Associates Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=11.52/20.821550024552
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Renal Associates Holdings Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of American Renal Associates Holdings's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


American Renal Associates Holdings (American Renal Associates Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 6550, Beverly, MA, USA, 01915
American Renal Associates Holdings Inc is a joint venture-focused dialysis services provider in the United States. The company through its subsidiary is engaged in providing kidney dialysis services for patients suffering from chronic kidney failure, also known as end-stage renal disease. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure.
Executives
Don E Williamson officer: EVP, Chief Operating Officer 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Victoria Labriola officer: VP and General Counsel AMERICAN RENAL HOLDINGS, INC. 500 CUMMINGS CENTER, SUITE 6550 BEVERLY MA 01915
Joseph A Carlucci director, officer: Chief Executive Officer C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Syed T Kamal director, officer: President C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Jeremy Gelber director C/O CENTERBRIDGE PARTNERS, L.P., 375 PARK AVE, 12TH FLOOR, NEW YORK NY 10152
Christopher J Hocevar director 1601 CHESTNUT STREET SHAREHOLDER SERVICES TL05Y PHILADELPHIA PA 19192
Robert H Fish director C/O SKILLED HEALTHCARE 27442 PORTOLA PARKWAY, SUITE 200 FOOTHILL RANCH CA 92610
Michael Boxer director 9151 BOULEVARD 26 NORTH RICHLAND HILLS TX 76180
John M Jureller director FRONTIER COMMUNICATIONS, 401 MERRITT 7, NORWALK CT 06851
Thomas W Erickson director OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Jason Boucher officer: Former VP & CFO 500 CUMMINGS CENTER SUITE 6550 BEVERLY MA 01915
Mark Herbers officer: Interim CFO and Interim CAO 500 CUMMINGS CENTER, SUITE 6550, BEVERLY MA 01915
Michael Ray Costa officer: VP and General Counsel C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915
Patrick T Ryan director 401 EDGEWATER PLACE, SUITE 500, WAKEFIELD MA 01880
Jonathan L Wilcox officer: VP & Chief Financial Officer C/O AMERICAN RENAL ASSOCIATES HOLDINGS 500 CUMMINGS CENTER BEVERLY MA 01915

American Renal Associates Holdings (American Renal Associates Holdings) Headlines

From GuruFocus